Genfit S.A. (GNFT.PA)
EUR 3.5
(2.04%)
EUR 3.5
(2.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -26.58 Million EUR | -32.69% |
| 2022 | -27.54 Million EUR | -135.9% |
| 2021 | 76.73 Million EUR | 198.65% |
| 2020 | -77.79 Million EUR | -34.51% |
| 2019 | -57.83 Million EUR | 16.77% |
| 2018 | -69.48 Million EUR | -22.56% |
| 2017 | -56.69 Million EUR | -65.98% |
| 2016 | -34.15 Million EUR | -93.25% |
| 2015 | -17.67 Million EUR | -2.42% |
| 2014 | -17.25 Million EUR | -64.15% |
| 2013 | -10.51 Million EUR | -36.26% |
| 2012 | -7.71 Million EUR | 0.46% |
| 2011 | -7.75 Million EUR | -1.21% |
| 2010 | -7.65 Million EUR | -18.28% |
| 2009 | -6.47 Million EUR | -25.14% |
| 2008 | -5.17 Million EUR | 13.63% |
| 2007 | -5.99 Million EUR | -982.7% |
| 2006 | -553.3 Thousand EUR | -133.01% |
| 2005 | 1.67 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 31.22 Million EUR | 0.0% |
| 2023 Q3 | 2.81 Million EUR | 111.87% |
| 2023 FY | -36.55 Million EUR | -32.69% |
| 2023 Q2 | -23.74 Million EUR | 0.0% |
| 2023 Q4 | -16.32 Million EUR | -679.45% |
| 2022 Q2 | -17.49 Million EUR | 0.0% |
| 2022 Q3 | 5.31 Million EUR | 130.35% |
| 2022 FY | -27.54 Million EUR | -135.9% |
| 2022 Q4 | 6.09 Million EUR | 14.78% |
| 2021 Q2 | -31.47 Million EUR | 0.0% |
| 2021 Q4 | 58.68 Million EUR | 0.0% |
| 2021 FY | 76.73 Million EUR | 198.65% |
| 2020 Q4 | -32.03 Million EUR | 0.0% |
| 2020 FY | -77.79 Million EUR | -34.51% |
| 2020 Q2 | -54.48 Million EUR | 0.0% |
| 2019 Q4 | -10.23 Million EUR | 0.0% |
| 2019 FY | -57.83 Million EUR | 16.77% |
| 2019 Q2 | -51.3 Million EUR | -278.02% |
| 2019 Q1 | -13.57 Million EUR | 64.22% |
| 2018 FY | -69.48 Million EUR | -22.56% |
| 2018 Q4 | -37.93 Million EUR | 0.0% |
| 2018 Q2 | -31.55 Million EUR | -83.2% |
| 2018 Q1 | -17.22 Million EUR | 49.8% |
| 2017 Q4 | -34.31 Million EUR | 0.0% |
| 2017 FY | -56.69 Million EUR | -65.98% |
| 2017 Q1 | -14.2 Million EUR | 33.35% |
| 2017 Q2 | -22.37 Million EUR | -57.47% |
| 2016 FY | -34.15 Million EUR | -93.25% |
| 2016 Q2 | -12.84 Million EUR | -53.25% |
| 2016 Q1 | -8.38 Million EUR | 1.93% |
| 2016 Q4 | -21.31 Million EUR | 0.0% |
| 2015 FY | -17.67 Million EUR | -2.42% |
| 2015 Q3 | -4.28 Million EUR | 53.09% |
| 2015 Q2 | -9.13 Million EUR | -113.15% |
| 2015 Q1 | -4.28 Million EUR | 46.98% |
| 2015 Q4 | -8.54 Million EUR | -99.47% |
| 2014 FY | -17.25 Million EUR | -64.15% |
| 2014 Q1 | -4.23 Million EUR | 13.47% |
| 2014 Q3 | -4.23 Million EUR | 53.94% |
| 2014 Q2 | -9.18 Million EUR | -117.09% |
| 2014 Q4 | -8.08 Million EUR | -90.89% |
| 2013 Q3 | -2.55 Million EUR | 53.72% |
| 2013 FY | -10.51 Million EUR | -36.26% |
| 2013 Q4 | -4.89 Million EUR | -91.24% |
| 2013 Q2 | -5.52 Million EUR | -116.06% |
| 2013 Q1 | -2.55 Million EUR | 0.0% |
| 2012 Q1 | -1.87 Million EUR | 0.0% |
| 2012 Q4 | -2.55 Million EUR | -36.58% |
| 2012 FY | -7.71 Million EUR | 0.46% |
| 2012 Q2 | -1.87 Million EUR | 0.0% |
| 2012 Q3 | -1.87 Million EUR | 0.0% |
| 2011 Q3 | -1.85 Million EUR | 0.0% |
| 2011 Q1 | -1.85 Million EUR | 0.0% |
| 2011 Q2 | -1.85 Million EUR | 0.0% |
| 2011 Q4 | -1.87 Million EUR | -0.84% |
| 2011 FY | -7.75 Million EUR | -1.21% |
| 2010 Q1 | -1.86 Million EUR | 0.0% |
| 2010 Q2 | -1.86 Million EUR | 0.0% |
| 2010 Q3 | -1.86 Million EUR | 0.0% |
| 2010 Q4 | -1.85 Million EUR | 0.32% |
| 2010 FY | -7.65 Million EUR | -18.28% |
| 2009 FY | -6.47 Million EUR | -25.14% |
| 2009 Q4 | -1.86 Million EUR | -20.14% |
| 2009 Q3 | -1.55 Million EUR | 0.0% |
| 2009 Q2 | -1.55 Million EUR | 0.0% |
| 2009 Q1 | -1.55 Million EUR | 0.0% |
| 2008 Q2 | -1.12 Million EUR | 0.0% |
| 2008 Q4 | -1.55 Million EUR | -37.65% |
| 2008 Q3 | -1.12 Million EUR | 0.0% |
| 2008 Q1 | -1.12 Million EUR | 0.0% |
| 2008 FY | -5.17 Million EUR | 13.63% |
| 2007 Q2 | -1.24 Million EUR | 0.0% |
| 2007 Q3 | -1.24 Million EUR | 0.0% |
| 2007 Q4 | -1.12 Million EUR | 9.66% |
| 2007 FY | -5.99 Million EUR | -982.7% |
| 2007 Q1 | -1.24 Million EUR | 0.0% |
| 2006 Q2 | -7225.00 EUR | 0.0% |
| 2006 Q4 | -1.24 Million EUR | -17162.28% |
| 2006 FY | -553.3 Thousand EUR | -133.01% |
| 2006 Q1 | -7225.00 EUR | 0.0% |
| 2006 Q3 | -7225.00 EUR | 0.0% |
| 2005 Q3 | 545.1 Thousand EUR | 0.0% |
| 2005 FY | 1.67 Million EUR | 0.0% |
| 2005 Q2 | 545.1 Thousand EUR | 0.0% |
| 2005 Q1 | 545.1 Thousand EUR | 0.0% |
| 2005 Q4 | -7225.00 EUR | -101.33% |
| 2004 Q4 | 545.1 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -679.015% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 79.133% |
| Adocia SA | -17.62 Million EUR | -50.834% |
| Aelis Farma SA | -6.46 Million EUR | -311.391% |
| Biophytis S.A. | -14.33 Million EUR | -85.446% |
| Advicenne S.A. | -6.45 Million EUR | -311.646% |
| genOway Société anonyme | 2.06 Million EUR | 1386.983% |
| IntegraGen SA | -183.77 Thousand EUR | -14363.732% |
| Medesis Pharma S.A. | -4.22 Million EUR | -528.467% |
| Neovacs S.A. | -6.9 Million EUR | -284.796% |
| NFL Biosciences SA | -4.43 Million EUR | -499.943% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -3315.412% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -747.238% |
| Sensorion SA | -22.31 Million EUR | -19.136% |
| Theranexus Société Anonyme | -7.64 Million EUR | -247.738% |
| TME Pharma N.V. | -5.62 Million EUR | -372.617% |
| Valbiotis SA | -7.16 Million EUR | -271.229% |
| TheraVet SA | -2.17 Million EUR | -1122.008% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -31.013% |
| argenx SE | -417.15 Million EUR | 93.628% |
| BioSenic S.A. | -7.04 Million EUR | -277.557% |
| Celyad Oncology SA | -8.45 Million EUR | -214.296% |
| DBV Technologies S.A. | -85.24 Million EUR | 68.82% |
| Galapagos NV | -88.26 Million EUR | 69.885% |
| GeNeuro SA | -14.35 Million EUR | -85.132% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -66.198% |
| Innate Pharma S.A. | -12.66 Million EUR | -109.803% |
| Inventiva S.A. | -102.7 Million EUR | 74.121% |
| MaaT Pharma SA | -19.94 Million EUR | -33.28% |
| MedinCell S.A. | -20.97 Million EUR | -26.71% |
| Nanobiotix S.A. | -26.77 Million EUR | 0.743% |
| Onward Medical N.V. | -35.46 Million EUR | 25.049% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -484.279% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -15.636% |
| Oxurion NV | -12.11 Million EUR | -119.488% |
| Pharming Group N.V. | -4.87 Million EUR | -444.723% |
| Poxel S.A. | -28.76 Million EUR | 7.593% |
| GenSight Biologics S.A. | -29.69 Million EUR | 10.493% |
| Transgene SA | -30.01 Million EUR | 11.435% |
| Financière de Tubize SA | -2.14 Million EUR | -1139.754% |
| UCB SA | 604 Million EUR | 104.401% |
| Valneva SE | -82.08 Million EUR | 67.62% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 7.827% |